(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 May 2022 (12.05.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/099074 A1

(51) International Patent Classification:
A61K 31/4375 (2006.01) *A61K 31/505* (2006.01)
A61K 31/44 (2006.01)

(21) International Application Number:
PCT/US2021/058337

(22) International Filing Date:
05 November 2021 (05.11.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/110,724 06 November 2020 (06.11.2020) US
63/138,285 15 January 2021 (15.01.2021) US

(71) Applicant: **DOT THERAPEUTICS-1, INC.** [US/US]; 2765 Sand Hill Road, Menlo Park, California 94025 (US).

(72) Inventors; and

(71) Applicants: **WRIGHT, Karen D.** [US/US]; 450 Brookline Avenue, Boston, Massachusetts 02215 (US). **HASSKOGAN, Daphne Adele** [US/US]; 450 Brookline Avenue, Boston, Massachusetts 02215 (US).

(72) Inventor: **BLACKMAN, Samuel C.**; 1539 Dolphin Bay Road, Eastsound, Washington 98245 (US).


(74) Agent: **PERLA, Luis**; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

WO 2022/099074 A1

(54) Title: RAF INHIBITOR FOR TREATING LOW GRADE GLIOMA

FIG. 2



(57) Abstract: Described herein are methods and compositions for treating gliomas such as pediatric low grade glioma. In some embodiments, a herein described method of treating pediatric low grade glioma comprises administering to a subject in need thereof (R)-2-(1-(6-amino-5-chloropyrimidine-4-carboxamido)ethyl)-N-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide (Compound A), or a pharmaceutically acceptable salt thereof. In some embodiments, Compound A or a pharmaceutically acceptable salt thereof is administered in an amount that is equivalent to about 400 mg/m^2 to about 600 mg/m^2 of Compound A per week. In some embodiments, the subject is less than 20 years of age.

[Continued on next page]

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*